Analysis of hepatic metabolism affecting pharmacokinetics of propranolol in humans

International Journal of Pharmaceutics

Volumn 349, Issue 1-2, 2008, Pages 53-60

  Kiriyama, A ^a   Honbo, A ^a   Iga, K ^a  

^a DOSHISHA WOMEN'S COLLEGE OF LIBERAL ARTS   (Japan)

Author keywords

Hepatic metabolism; Human; Pharmacokinetics; Physiologically based pharmacokinetic model; Propranolol

Indexed keywords

PROPRANOLOL;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG METABOLISM; LIVER METABOLISM; LIVER MICROSOME; MALE; NONHUMAN; PHARMACOKINETICS; PRIORITY JOURNAL; RAT;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; AREA UNDER CURVE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LIVER; MALE; MICROSOMES, LIVER; MODELS, BIOLOGICAL; PROPRANOLOL; RATS; RATS, WISTAR; TISSUE DISTRIBUTION;

EID: 37349077853     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2007.07.019     Document Type: Article

References (26)

1. Agoram B., Woltosz W.S., and Bolger M.B. Predicting the impact of physiological and biochemical processes on oral drug bioavailability. Adv. Drug Deliv. Rev. 50 (2001) S41-S67
2. Benet L.Z., Wu C.Y., Hebert M.F., and Wacher V.J. Intestinal drug metabolism and antitransport processes: a potential paradigm shift in oral drug delivery. J. Controll. Release 39 (1996) 139-143
3. Borgström L., Johansson C.G., Larsson H., and Lenander R. Pharmacokinetics of propranolol. J. Pharmacokinet. Biopharm. 9 (1981) 419-429
4. Brown R.P., Delp M.D., Lindstedt S.L., Rhomberg L.R., and Beliles R.P. Physiological parameter values for physiologically based pharmacokinetic models. Toxicol. Ind. Health 13 (1997) 407-484
5. Gomeni R., Bianchetti G., Sega R., and Morselli P.L. Pharmacokinetics of propranolol in normal healthy volunteers. J. Pharmacokinet. Biopharm. 5 (1977) 183-192
6. Goodman L.S., and Gilman A. In: Molinoff P.B., and Ruddon R.W. (Eds). Pharmacological Basis of Therapeutics. ninth ed. (1996), McGraw-Hill, Health Professions Division, New York
7. Houston J.B. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem. Pharmacol. 47 (1994) 1469-1479
8. Komura H., Kawase A., and Iwaki M. Application of substrate depletion assay for early prediction of nonlinear pharmacokinetics in drug discovery: assessment of nonlinearity of metoprolol, timolol, and propranolol. J. Pharm. Sci. 94 (2005) 2656-2666
9. Kopitar Z., Vrhova B., Lenardič A., Cvelbar P., Žorž M., and Francetić I. Dose-dependent bioavailability of propranolol. Int. J. Clin. Pharmacol. Ther. Toxicol. 24 (1986) 319-322
10. Lave T.H., Dupin S., Schmitt C., Chou R.C., Jaeck D., and Coassolo P.H. Integration of in vitro data into allometric scaling to predict hepatic metabolic clearance in man: application to 10 extensively metabolized drugs. J. Pharm. Sci. 86 (1997) 584-590
11. Lowry O.H., Rosebrough N.J., Farr A.L., and Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193 (1951) 265-275
12. Ludden T.M. Nonlinear pharmacokinetics. Clinical implications. Clin. Pharmacokinet. 20 (1991) 429-446
13. Masubuchi Y., Kagimoto N., Narimatsu S., Fujita S., and Suzuki T. Regioselective contribution of the cytochrome P-450 2D subfamily to propranolol metabolism in rat liver microsomes. Drug Metab. Dispos. 21 (1993) 1012-1016
14. McAinsh J., Baber N.S., Holmes B.F., Young J., and Ellis S.H. Bioavailability of sustained release propranolol formulations. Biopharm. Drug Dispos. 2 (1981) 39-48
15. Naritomi Y., Terashita S., Kimura S., Suzuki A., Kagayama A., and Sugiyama Y. Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans. Drug Metab. Dispos. 29 (2001) 1316-1324
16. Obach R.S. Nonspecific binding to microsomes: impact on scale-up of in vitro intrinsic clearance to hepatic clearance as assessed through examination of warfarin, imipramine, and propranolol. Drug Metab. Dispos. 25 (1997) 1359-1369
17. Obach R.S. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab. Dispos. 27 (1999) 1350-1359
18. Pang K.S., and Rowland M. Hepatic clearance of drugs. I. Theoretical consideration of a "well-stirred" and a "parallel tube" model. Influence of hepatic blood, plasma and blood binding and hepatocellular enzyme activity on hepatic drug clearance. J. Pharmacokin. Biopharm. 5 (1977) 625-653
19. Perkinson A. In: Klaassen C.D. (Ed). Biotransformation of Xenobiotics, Casarett & Doull's Toxicology. fifth ed. (1996), McGraw-Hill, Inc. 114-186 (Chapter 6)
20. Poulin P., and Theil F.-P. Prediction of pharmacokinetics prior to in vivo studies. II. Generic physiologically based pharmacokinetic models of drug disposition. J. Pharm. Sci. 91 (2002) 1358-1370
21. Routledge P.A., and Shand D.G. Clinical pharmacokinetics of propranolol. Clin. Pharmacokinet. 4 (1979) 73-90
22. Shand D.G., and Rangno R.E. The disposition of propranolol. I. Elimination during oral absorption in man. Pharmacology 7 (1972) 159-168
23. Suzuki T., Isozaki S., Ishida R., Saitoh Y., and Nakagawa F. Drug absorption and metabolism studies by use of portal vein infusion in the rat. II. Influence of dose and infusion rate on the bioavailability of propranolol. Chem. Pharm. Bull. 22 (1974) 1639-1645
24. Weidler D.J., Jallad N.S., Garg D.C., and Wagner J.G. Pharmacokinetics of propranolol in the cat and comparisons with humans and three other species. Res. Commun. Chem. Pathol. Pharmacol. 26 (1979) 105-114
25. Yamaoka K., Tanigawara Y., Nakagawa T., and Uno T. A pharmacokinetic analysis program (MULTI) for microcomputer. J. Pharmacobio-Dyn. 4 (1981) 879-885
26. Yasuhara M., Yatsuzuka A., Yamada K., Okumura K., Hori R., Sakurai T., and Kawai C. Alteration of propranolol pharmacokinetics and pharmacodynamics by quinidine in man. J. Pharmacobio-Dyn. 13 (1990) 681-687